Whitfield Assists Ascletis Pharma on its Share Placing
Overview
The source reports Ascletis Pharma’s placing of 69,256,000 shares.
Timetable
The offering was announced February 3, 2026 and reportedly completed February 10.
Agent and proceeds
Citigroup Global Markets is identified as sole placing agent, with expected net proceeds of approximately HK $835.3 million after commissions and estimated expenses.
Legal work
Mengyu Lu, Justin Zhou, Sierra Tao and Claire Chen are named on capital markets. The amount describes expected net fundraising proceeds, rather than the company’s market capitalization or a clinical-development result, and this record does not infer a share placing price not stated in the source body.
